Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precision-recall curves after applying BAGELalgorithm to the screening data. F measure provided in the inset represents the harmonic mean ofprecision & recall of the screen.